Decitabine (NSC 127716)

For research use only. Not for use in humans.

製品コードS1200 別名:Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR

Decitabine (NSC 127716)化学構造

CAS No. 2353-33-5

Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

サイズ 価格(税別)  
10mM (1mL in DMSO) JPY 27700
JPY 16900
JPY 30200
JPY 55100
JPY 96600
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:sales[email protected]

バルク問合せ

文献中Selleckの製品使用例(101)

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M1fxXWZ2dmO2aX;uJGF{e2G7 MX:wMlXDqM7:TR?= MUiyOEBp NWKweGRLf2G2ZYK= NHvmNllud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? MnzLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109 NU\tUm5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKwMlUwOi53L{Wg{txO MVSyOE81QC95MjDo M3S1WJdifGW{ NXPYO2FucW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MnfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109 NV3EfXZGTnWwY4Tpc44hSXO|YYm= MY[wMlXDqM7:TR?= MlXDOk8yOi9{NDDo NHTwUW94[XSnch?= MWjpcohq[mm2czDj[YxtKG2rZ4LheIlwdsLi M4faXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN|A5OjxxYU6=
Eca109 Mnz4SpVv[3Srb36gRZN{[Xl? NULJT3ByOC53wrFOwG0> NYH2XIg6OjRiaB?= NYDrcIxMf2G2ZYK= M3HQdYlvcGmkaYTzJINmdGxiaX72ZZNqd25? NFWyfVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyN|A5Oid-MkWxNlMxQDJ:L3G+
Eca109 NUHKZ3h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTyNE42yqEQvF2= MkjsNlQhcA>? MonNe4F1\XJ? NIW2SI9qdmS3Y3XzJGczN01iYYLy[ZN1KGmwIITo[UBk\WyuIHP5Z4xm M1nXdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN|A5OjxxYU6=
Eca109 MYLGeY5kfGmxbjDBd5NigQ>? MmTZNE42NzFizszN NEfWWY4zPCCq NHTLXoV4[XSnch?= NH7IVo5l\WO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDOSk3PwkJ{IHHu[EBOVVB{ NUPrUItXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
SW1116  NIf5WGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvLXmgxNjVxMT:yM|Uh|ryP MnTMOFghcA>? MkHySG1UVw>? MonC[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> MkfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{SyPFYoRjJ2OEe0Nlg3RC:jPh?=
LOVO NGX4TWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrVNE42NzFxMj:1JO69VQ>? MXu0PEBp NXnVW3d3TE2VTx?= NXzXcJNj\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? NFS0Znc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O|QzQDZ:L3G+
SW1116  NULISlc1TnWwY4Tpc44hSXO|YYm= M4jYZ|ExKM7:TR?= MmPDOFghcA>? MkXpSG1UVw>? Ml3MbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj M4LwNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
LOVO MlnySpVv[3Srb36gRZN{[Xl? MnfsNVAh|ryP M4T4WVQ5KGh? MYLEUXNQ M1\YRolv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? NYPmOpJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|QzQDZpPkK0PFc1Ojh4PD;hQi=>
SW1116  NWfVPWl[SXCxcITvd4l{KEG|c3H5 MlvsNVAh|ryP NIDScVc1QCCq MYnEUXNQ NVfOXWJM\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ MmnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{SyPFYoRjJ2OEe0Nlg3RC:jPh?=
LOVO NWnsSlB3SXCxcITvd4l{KEG|c3H5 NWHEOHFGOTBizszN NYHCOFdbPDhiaB?= NVnNdHptTE2VTx?= NWnaUlV1\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
RPMI-8226 NU\mTZpSSXCxcITvd4l{KEG|c3H5 MYWxM|Ih|ryP MkjoOFgwPzJxOU[gbC=> MX3EUXNQ M3vtTYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NWfReIZYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|MyODhpPkK0PFM{OTB6PD;hQi=>
OPM-2  NXL3Roh6SXCxcITvd4l{KEG|c3H5 NWTOdo9JOS9{IN88US=> Ml7sO|IwQTZxMUKwJIg> NEPacnpFVVOR M3L3fYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NXv5eWsyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|MyODhpPkK0PFM{OTB6PD;hQi=>
JJN3  NIO4e2NCeG:ydH;zbZMhSXO|YYm= MV2wMlUwOSEQvF2= Mn3CNlQwPDhiaB?= NFzJWYVFVVOR Mn\tbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
NCI-H929  NWriN3piSXCxcITvd4l{KEG|c3H5 NYC0NnhDOS9{IN88US=> NYXSS2RvPzJxOU[vNVIxKGh? M1HTd2ROW09? M4D3dIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
RPMI-8226 M{X5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnadYc6OS9{IN88US=> MkjhNlQwPDhxN{KgbC=> M1[zUWROW09? NYXIOIoy[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NV\0eIN[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|MyODhpPkK0PFM{OTB6PD;hQi=>
OPM-2  NI\NXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDCWZEyNzJizszN NW[3OlJPOjRxNEivO|IhcA>? MVPEUXNQ MknsZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? NHP6[XI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
JJN3  NXrJO4tDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6wMlUwOSEQvF2= M4rYRVI1NzR6L{eyJIg> MkHSSG1UVw>? NWHhPGY5[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NHPObY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
NCI-H929  NU[0b|BlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PpWVEwOiEQvF2= MojENlQwPDhxN{KgbC=> M2O0cGROW09? NUW4PWp4[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
HeLa MmfHT4lv[XOnIFHzd4F6 MX\LbV0yODBy4pETOVAxOCEQvF2g[o9zKGiHTmSx NID0XlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4NFA6QCd-MkS3PFAxQTh:L3G+
HeLa MnPBT4lv[XOnIFHzd4F6 NGTCPYpMcT13Lk[gxtEhOC53IN88UUBnd3JiaFXOWFI> M4jRR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{iwNFk5Lz5{NEe4NFA6QDxxYU6=
HeLa NVizN3FkU2mwYYPlJGF{e2G7 NWPz[oo2U2l;MkGuOkDDuSB|LkCg{txOKG[xcjDoR25VOQ>? Moq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OECwPVgoRjJ2N{iwNFk5RC:jPh?=
HeLa NIG0T|dMcW6jc3WgRZN{[Xl? NVLSWpA2U2l;MUSuOEDDuSB2Lk[g{txOKG[xcjDoR25VOw>? MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6MEC5PEc,OjR5OECwPVg9N2F-
NB4 M3z0emZ2dmO2aX;uJGF{e2G7 NVW1SJFwOi53L{WvO{42NzFyIN88US=> MoGyNlQhcA>? NX\6OnlDTE2VTx?= NHHEd5FqdmO{ZXHz[YEhfGinIHX4dJJme3Orb36gc4YheHKnY4Xyd49zKG2rUj2xNlVi Ml62QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OES4O|AoRjJ2NEi0PFcxRC:jPh?=
CD4+ CD25− T  MnroSpVv[3Srb36gRZN{[Xl? MmnFNU82KM7:TR?= MkTWdoVlfWOnUzDncI9j[WxiRF7BJI1mfGi7bHH0bY9v NGXaTHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3OlM3OCd-MkS0O|Y{PjB:L3G+
BV-173 MYHBdI9xfG:|aYOgRZN{[Xl? NFXDc48xNjJ3L{CuOU8xNjd3L{Gg{txO NH;ofoM1QC95Mj:5OkBp NX3YU5dmyqCSQmO= MYfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MkDGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkO2NVMoRjJ2NEKzOlE{RC:jPh?=
ML-1 MlHJRZBweHSxc3nzJGF{e2G7 MlHoNE4zPS9yLkWvNE44PS9zIN88US=> M1XEXFQ5Nzd{L{m2JIg> NYrCNXNJyqCSQmO= MlHMbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NYHFRpljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
HL-60 Mn3MRZBweHSxc3nzJGF{e2G7 MV2wMlI2NzBwNT:wMlc2NzFizszN Mn7EOFgwPzJxOU[gbC=> NWPXc4RnyqCSQmO= MWXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
KG-1a MWTBdI9xfG:|aYOgRZN{[Xl? M1\4SlAvOjVxMD61M|AvPzVxMTFOwG0> MWO0PE84Oi97NjDo NV60XolvyqCSQmO= MV;pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NFTFS209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
BV-173 M3viPWZ2dmO2aX;uJGF{e2G7 MW[yOVAwPTBybl2= MVm0PEBp MVVCpHBDWw>? M4fnR4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= Mo\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkO2NVMoRjJ2NEKzOlE{RC:jPh?=
CEM NITyO3dHfW6ldHnvckBCe3OjeR?= MYqyOVAwPTBybl2= NH7QW441QCCq Mmi5xsBRSlN? NF3w[IpqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NXfOSJlyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
HL-60 Mk\lSpVv[3Srb36gRZN{[Xl? M1X3S|I2OC93MEDuUS=> MlS1OFghcA>? M1:xPeKhWEKV M1LVNIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NXjFN3d6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
ML-1 NIjDOGpHfW6ldHnvckBCe3OjeR?= M1jnOFI2OC93MEDuUS=> MWm0PEBp MnLJxsBRSlN? MWjpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? M2rvTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
DLD-1 NHTuWZpHfW6ldHnvckBCe3OjeR?= MmnSNlUxNzVyMH7N NULVNYdZPDhiaB?= M1K5NeKhWEKV NHf4PYVldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NUfMVnVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
HCT-116 Mnq3SpVv[3Srb36gRZN{[Xl? MlXCNlUxNzVyMH7N M4PaVVQ5KGh? NEjqSnrDqFCEUx?= NGfKTY5ldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NXTLXm5NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
U937-A/E-9/14/18  MYHBdI9xfG:|aYOgRZN{[Xl? MnO3NE4xOS9yLkGvNU8yOCEQvF2= M4DW[|Q5KGh? MYLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDNyMES1Okc,OjR|MEC0OVY9N2F-
HT29 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm4R|k3PzJiaB?= M1PYSGlEPTB;MUSwNOKyOTd7IN88US=> NV3u[oZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO|IxPjFpPkK0NVczODZzPD;hQi=>
SW48 NYPSSGhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLvWFhMPzJiaB?= NFXtUFJKSzVyPUG1MlLDuTZwMjFOwG0> MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5MkC2NUc,OjRzN{KwOlE9N2F-
HCT116 MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P2SFczKGh? NXPVNmdkUUN3ME2xMlfDuTBwNDFOwG0> MmL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{KwOlEoRjJ2MUeyNFYyRC:jPh?=
HepG2 M3rHWmZ2dmO2aX;uJGF{e2G7 MYWwMlUwOSEQvF2= MmewNlQhcA>? Mki5SG1UVw>? M3\QWJVxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NUHrSHhiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFY5PzRpPkK0NVQ3QDd2PD;hQi=>
LS174T NVLTOVMxTnWwY4Tpc44hSXO|YYm= NX2zWHVkOC53L{Gg{txO MYiyOEBp NYjuc5lvTE2VTx?= MWPs[YFlKHSxIHHuJIlv[3KnYYPlJI9nKE:FVF6yJIxmfmWucx?= NGLr[Ic9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG0Olg4PCd-MkSxOFY5PzR:L3G+
HepG2 MUXBdI9xfG:|aYOgRZN{[Xl? MXKxM|ExNzFyMDFOwG0> MX63JIQ> MmjaSG1UVw>? M1jONolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MkP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O|QoRjJ2MUS2PFc1RC:jPh?=
LS174T MmKxRZBweHSxc3nzJGF{e2G7 MX[xM|ExNzFyMDFOwG0> M4rBS|ch\A>? NY[3e4czTE2VTx?= NVTTc5plcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MlTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O|QoRjJ2MUS2PFc1RC:jPh?=
QBC-939 NX\5[m5sSXCxcITvd4l{KEG|c3H5 Mly1NU8yOC9zMECg{txO MnfMO{Bl MY\EUXNQ MXfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHTwcWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG0Olg4PCd-MkSxOFY5PzR:L3G+
U251 MXLBdI9xfG:|aYOgRZN{[Xl? M3H5NlEwOTBxMUCwJO69VQ>? MmT3O{Bl NF;yeYZFVVOR NVy0c5FrcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O|Q9N2F-
HL-60 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\UNUDPxE1? NUC1N5NKPDhiaB?= MVHpcoNz\WG|ZYOgS|IueGijc3WgZ4VtdCCocnHjeIlwdg>? MlzIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMECzNlQoRjJ2MECwN|I1RC:jPh?=
MDA‑MB‑453 NIjmXZRHfW6ldHnvckBCe3OjeR?= NF;mfnQxNjJxMTFOwG0> MWO3NkBp MoPsZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NEKyPEc,OjN6NESyNlg9N2F-
HCC1569 M1zFTGZ2dmO2aX;uJGF{e2G7 NGe5e4QxNjJxMTFOwG0> M3TqR|czKGh? NX7UR4N[[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NEKyPEc,OjN6NESyNlg9N2F-
BT‑474 MX3GeY5kfGmxbjDBd5NigQ>? MmfSNE4zNzFizszN MoLsO|IhcA>? M1T2V4NifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NEKyPEc,OjN6NESyNlg9N2F-
AGS NX73cmJvSXCxcITvd4l{KEG|c3H5 NXqyUVZRPS9zMD:yNE82OCEQvF2= NWnEOFJ4PDkEoHlCpC=> NYPDcWpHTE2VTx?= NU\OO4E1cW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV6Mke4OEc,OjN3OEK3PFQ9N2F-
A549 MkDVRZBweHSxc3nzJGF{e2G7 M3y0XVUwOTBxMkCvOVAh|ryP MYW0POKhcMLi MUfEUXNQ NWL4VHROcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? NXLVUll1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PFI4QDRpPkKzOVgzPzh2PD;hQi=>
AGS  MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnWyOU8yOC9{MD:1NEDPxE1? NEnMPWw1QMLiaNMg NIPaOFdFVVOR M3HHcYlv\HWlZYOgS|IwVSCyaHHz[UBienKnc4VCpC=> M2rxWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUiyO|g1Lz5{M{W4Nlc5PDxxYU6=
Kasumi-1 MUfBdI9xfG:|aYOgRZN{[Xl? M3XWOlAvPSEQvF2= MXy0POKhcMLi MXnk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= NFSxZ|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5N|M1QCd-MkO0PVM{PDh:L3G+
OCI-AML3 NIX1bnpCeG:ydH;zbZMhSXO|YYm= NFryOXYzNjVizszN MYK0POKhcMLi NVfa[|RW\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7M{O0PEc,OjN2OUOzOFg9N2F-
MV4-11 MlfIRZBweHSxc3nzJGF{e2G7 NIPXW4wzNjVizszN M4i0VFQ5yqCqwrC= NHfKZ|Nl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> NFm1c449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5N|M1QCd-MkO0PVM{PDh:L3G+
NK  M4L5S2N6fG:2b4jpeJkhSXO|YYm= NWP6WI9UOC5yMj2yNEDPxE1? MlTSOUBl NVzDS5Uy\GWlcnXhd4V{KHSqZTDjfZRwdHm2aXOgZYN1cX[rdImgc4YhVktiY3XscJMh[XRiaX70[ZJu\WSrYYTlJINwdmOnboTyZZRqd26|IILld5VtfGmwZzDpckBiKFVvc3jhdIVlKGSxc3ZihLNz\XOyb37z[UBkfXK4ZR?= NFzXdZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OyPFA5QCd-MkOzNlgxQDh:L3G+
NK  M4DFO2Fxd3C2b4Ppd{BCe3OjeR?= MonRNE4xOi1{MDFOwG0> MWK1JIQ> M{nwWoRm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>? MnjuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MkiwPFgoRjJ|M{K4NFg5RC:jPh?=
NK  NUf5XYRMTnWwY4Tpc44hSXO|YYm= M37mPFAvODFvMkCg{txO NFzUR282KGR? MVTjZZV{\XNiaInwc41mfGi7bHH0bY9vKG:oIF7LJINmdGy|IHnuJIEh\G:|ZfMAl5Jme3CxboPl NED5eYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OyPFA5QCd-MkOzNlgxQDh:L3G+
MOLT4/DNR NHHVTmJHfW6ldHnvckBCe3OjeR?= NE\mUWo2KM7:TR?= NXLoPFNkPCCm M2r2TJJm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4MEW3NEc,OjNyNkC1O|A9N2F-
Jurkat/DOX M360OGZ2dmO2aX;uJGF{e2G7 MYO1JO69VQ>? M4DkOlQh\A>? MXny[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> Ml[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkC1O|AoRjJ|ME[wOVcxRC:jPh?=
MOLT4/DNR MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjxSZM2KM7:TR?= NG\OR|c1KGR? MULy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 M4H1OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
Jurkat/DOX MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HidlUh|ryP NWDtNGlFPCCm M3Xmd5Jm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= M{P6O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
ccRCC  NFPTNWtCeG:ydH;zbZMhSXO|YYm= MXywMlAyNTFyzszN MnrmO|IhcA>? M3H1fGROW09? M1\RbIhieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? NFe3PJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
TNBC  Mkm0RZBweHSxc3nzJGF{e2G7 NYe0U4hDOC5yMT2xNO69VQ>? NIHscHk4OiCq NUj0UXJ4TE2VTx?= MnTZbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? NEnvdWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
A498 MofXRZBweHSxc3nzJGF{e2G7 MoH6NE4xOS1zMN88US=> NVHHZ3AxPzJiaB?= MnnzSG1UVw>? NYjlV5RLcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? MlS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6Mk[0OlcoRjJ{OEK2OFY4RC:jPh?=
KIJ265T NEDoO|dCeG:ydH;zbZMhSXO|YYm= MnTnNE4xOS1zMN88US=> M3rYTlczKGh? M3i1TWROW09? MmHKbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
MDA-231 MnjDRZBweHSxc3nzJGF{e2G7 NI\GVoUxNjBzLUGw{txO M3[4TVczKGh? M2fld2ROW09? M{TFO4lv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> NFO2PWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
BT-20 M2S4NWFxd3C2b4Ppd{BCe3OjeR?= MnfSNE4xOS1zMN88US=> NH3uW|Q4OiCq NFTieo9FVVOR MWnpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NG\aNnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
U937 NF\QdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;5[2Y2NTJyIN88US=> NXPW[3hKOjRxNEivO|IhcA>? NYPY[5BpcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
HL60 M2TvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy1MVIxKM7:TR?= MkHXNlQwPDhxN{KgbC=> NWjocJZCcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NXKxV|FxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OlcxOjFpPkKyO|Y4ODJzPD;hQi=>
U937 M2TNWWFxd3C2b4Ppd{BCe3OjeR?= MYGxOUDPxE1? Mmn0NlQwPDhxN{KgbC=> Ml\0bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NH\GPYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke2O|AzOSd-MkK3OlcxOjF:L3G+
HL60 MUXBdI9xfG:|aYOgRZN{[Xl? NFvWUJoyPSEQvF2= MnvVNlQwPDhxN{KgbC=> NXXpRoNFcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NFzGcIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke2O|AzOSd-MkK3OlcxOjF:L3G+
LS411N  M2r2fGFxd3C2b4Ppd{BCe3OjeR?= MV2wMlUh|ryP Mn7wO|IhcA>? NFznWGRqdmO{ZXHz[ZMhTmG|IH3SUmEhdGW4ZXy= M3vEXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NE[xOlk2Lz5{MkS2NVY6PTxxYU6=
MDA-MB-231 M1nr[mFxd3C2b4Ppd{BCe3OjeR?= NVX6SXJ3OTBizszN NF7kN3k1QCCq NF\Obotz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NW[0cFdKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4PFc3QTdpPkKxPFg4Pjl5PD;hQi=>
MCF-7  MmflRZBweHSxc3nzJGF{e2G7 Ml;aNVAh|ryP NXPBd5hFPDhiaB?= M2fEfJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4HpbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEi3Olk4Lz5{MUi4O|Y6PzxxYU6=
A375 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfaZVdQOC53IN88US=> MUmxM|UwQCCm MVjpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
SKMEL1 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVGwMlUh|ryP NYPwbGxUOS93L{ig[C=> NX73cnU2cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NF31[nM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5OlYzOid-MkG3PVY3OjJ:L3G+
SKMEL3 M{nnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPMcGMxNjVizszN NH;zbYoyNzVxODDk M{PHcYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MorNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
SKMEL28 NGDiVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\sNE42KM7:TR?= MV2xM|UwQCCm NXPTZZFocW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= Ml:zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
MeWo NYXaRWIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fMflAvPSEQvF2= NIPUZXcyNzVxODDk NF;YRnBqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
B16 NIXId2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4C1NlAvPSEQvF2= Mny3NU82NzhiZB?= Mm\lbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
Ly 1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:yOEBp MliwTWM2OD15LkOg{txO M4foS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 7 NVrTSmg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET0RngzPCCq MmPiTWM2OD1zMD63JO69VQ>? NFy4eFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Su-DHL6 MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzOO2EzPCCq NF25[GlKSzVy78{eNlAh|ryP MmXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 10 MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOyOEBp MYjJR|Ux97zgMkCg{txO MlfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
RIVA NVrmdmNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWyOEBp M4XUcGlEPTExvK6yNEDPxE1? M3XoS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL2 M3L1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f5fVI1KGh? NYXwV2poUUN3MP-8olIxKM7:TR?= MoOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 1 MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoP1OFghcA>? MlH1TWM2OD1yLkO0JO69VQ>? NVG5e2dyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 7 NInPNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:1OFghcA>? M4DrSGlEPTB;MD6wNlUh|ryP NYDldVJyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Su-DHL6 NGHITmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\I[FZOPDhiaB?= NV30e2NsUUN3MP-8olIxKM7:TR?= M{Th[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 10 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLxWWU1QCCq M2exSGlEPTB;MT64JO69VQ>? M2ewVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
RIVA Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmKzOFghcA>? NEjLfIJKSzVy78{eNlAh|ryP M1jmW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL2 NXfJZ4VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHzOFghcA>? MVPJR|UxRTF5LkSg{txO NU\reVlyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 1 MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDnZnY4OiCq M4LZXmlEPTB;MD6wNUDPxE1? NUe2eY9JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 7 NIG2ZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\OclczKGh? MnrKTWM2OD1yLkCxPEDPxE1? MoLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Su-DHL6 MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq4O|IhcA>? MXLJR|UxRTFwNjFOwG0> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 10 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe4SYg4OiCq MUjJR|UxRTFwMjFOwG0> NYrkb3lvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
RIVA NE\XOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojyO|IhcA>? MkPXTWM2OO,:nkKwJO69VQ>? NF:3OmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Su-DHL2 M{G5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF20OYQ4OiCq NIPQV|hKSzVyPUGxMlIh|ryP NUC1b4lqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
U373-MAGI MYHBcpRqfmm{YXygZZN{[Xl? NYL0UHV3OC5{NTD0c{A5KHWP NU\qTYM2OiC2bzC3NkBpenN? MUfBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDWV3YuTyCyc3X1[I91gXCnZDDITXYuOSCQTEStN{Bqdm[nY4Tl[EBqdiCqdX3hckBWOzd|LV3BS2kh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIGW1MYdi\yCuZY\lcEBifCByLkK1JJRwKDhidV2gZYZ1\XJiMjD0c{A4OiCqcoOgZpkheVCFUjDt[ZRpd2R? NWDyXItqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVczPjBpPkK3NVE4OjZyPD;hQi=>
U373-MAGI M3PsUmFvfGm4aYLhcEBie3OjeR?= MXSwMlI2KHSxIEigeW0> NVvVRlM{OiC2bzC3NkBpenN? NFrDNZVCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBXW1ZvRzDwd4V2\G:2eYDl[EBJUVZvMTDOUFQuOyCrbn\lZ5Rm\CCrbjDoeY1idiCXM{ezMW1CT0liY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJIdi\yCuZY\lcEBifCByLkK1JJRwKDhidV2gZYZ1\XJiMjD0c{A4OiCqcoOgZpkheVCFUjDt[ZRpd2R? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{K2NEc,OjdzMUeyOlA9N2F-

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
- 合併

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
- 合併
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
- 合併
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
別名 Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR
Smiles C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04854889 Recruiting Drug: Decitabine Refractory Aplastic Anemia Institute of Hematology & Blood Diseases Hospital April 22 2021 Phase 2
NCT04086238 Completed Drug: Decitabine Healthy EpiDestiny Inc. October 8 2019 Phase 1
NCT04113616 Recruiting Drug: KRT-232|Drug: Cytarabine|Drug: Decitabine Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN) Kartos Therapeutics Inc. September 25 2019 Phase 1|Phase 2
NCT03875287 Recruiting Drug: Decitabine|Drug: Cedazuridine Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals Inc. April 17 2019 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferaseシグナル伝達経路

Tags: Decitabine (NSC 127716)を買う | Decitabine (NSC 127716) ic50 | Decitabine (NSC 127716)供給者 | Decitabine (NSC 127716)を購入する | Decitabine (NSC 127716)費用 | Decitabine (NSC 127716)生産者 | オーダーDecitabine (NSC 127716) | Decitabine (NSC 127716)化学構造 | Decitabine (NSC 127716)分子量 | Decitabine (NSC 127716)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID